• There are no suggestions because the search field is empty.

How do you reduce the Cost of Goods, which is key to affordable ATMPs?

Author Avatar
Dominiek Rossillion, Division Head Quality Assurance at QbD Group
Pharma & Biotech

The sales price of cell and gene therapies is influenced by multiple factors like Cost of Goods (COG), regulatory requirements, target market (or commercial aspect), and the development just to name a few. In this blog post you will learn more about the GOC aspect: what is this cost comprised of and how can you reduce it?

How do you reduce the Cost of Goods, which is key to affordable ATMPs? | QbD Group
6:30

Todayonly 18 cell and gene therapies have made it to the FDA approved therapies list. Only 14 have been approved for the European market. This means that very few therapies have made it to the market. In the US, the average market entry price of a therapy (excluding the tissue engineering field) is 541k USD. So they are not only rarer, but also much more expensive than traditional medicines. 

The sales price is influenced by multiple factors like Cost of Goods (COG), regulatory requirements, target market (or commercial aspect), and the development just to name a few. In this blog post one will be highlighted. You will learn more about the GOC aspect: what is this cost comprised of and how can you reduce it? 

For other factors stay tuned by subscribing to new articles.

 

Broadening the field

 

‘From needle to needle’ is the routine flow of a production cycle: from the patient sample collection until the injection of the final cell therapy product. In case of allogenic cell therapies the route can start with the collection from multiple different patients and finishing with the injection of the final product in a broad cohort of receiver.

Typically, a routine manufacturing process can be divided into four subcategories, each with corresponding costs: the sample collection cost, the processing cost, the capital cost, and the delivery cost.

Sample collection

The sample collection is a quite straightforward step. The ways in which a collection can be organized, are limited. The cost typically consists of the medical procedure and tools used to collect, store, and transport the sample. There aren’t many ways in which this cost can reduced. A possible approach is to focus on allogenic therapies instead of autologous ones. From a cost of goods perspective there are not many alternatives and even if they are available, the cost reduction often doesn’t justify the effort it takes to tackle this aspect first. Furthermore, blood collection is a daily and standardized routine.

The processing cost

The processing cost consists of the operational cost, the yield and the QC cost. The operational cost is largely consumed by labor, process aids and consumables costs that are required to run through the entire process (this section ranges from growth media to T-flasks, tubing and single use items, e.g. single use bioreactors).

The yield depends on the type of therapy. For autologous therapies, a minimum quantity is required, whereas for allogenic therapies there is value to be gained in producing in multiples of the minimum quantity, as this can be used for other patients as well.

Quality control cost encompasses every action to verify that production is running on target. Typically, this consists of sample analysis of intermediary process stages and the end product. The overhead cost of skilled operators, the lab equipment and keeping it calibrated and validated is also a significant chunk. QC is a key step to releasing the final product to the patient. It is however a verification, and does not alter the product created.

 

Capital cost 

 

The capital cost consists of process equipment and facility investment costs. This ranges from the clean room, the non-disposable equipment used to process the cell therapy and the development of the cell therapy that needs to be recovered. This cost is highly dependent on the specifics of the cell therapy. In general, the following adagio applies: the higher the automation and closedness of a system, the more robust the process result will be, but also the more expensive (from an initial investment perspective). 

Delivery cost

The delivery cost completes our delivery chain. This phase is analogue to the collection cost. The cell therapy needs to be transferred, stored, and injected into the patient during a medical procedure. Cost reduction options in this phase are fairly limited, given the already standardized procedure. 

Conclusion

When evaluating and allocating costs of cell therapies to these subdivisions, a few things come to mind. the ways to immediately optimize the sample collection and the delivery are limited.

Two large cost areas that can be studied and designed are the processing and the capital cost. They act as a balancing force. The more development time is spent on optimizing and automating, the more robust the cell therapy will become and the less manual labor and consumables or process aids will be required. This can also impact the level of assuredness or QC that is required.

The key point is to find the balance between capital expenditures and operational costs. There is only one way to achieve this: you should systematically assess the risks and the benefits involved, by offsetting it to scientifically sound data, and make investment calls based on that data.

And that is precisely what QbD can do for you. Our company is your perfect development partner for ATMP companies out there. If you want to learn more, please check out our electronic solution branded “Cell by Design”.

Putting theory to practice

For a recent project, the COG approach was intertwined with the assessment of the development strategy of a cell therapy. For multiple potential process improvement options (intended to close and automate to a certain or full extent) a calculation was made for three scenarios: targeted demand (1x), low demand (0,5 x) and high demand (5x). For each of those multiple process improvement options the costs (taking into account all factors listed above) were calculated and plotted in a graph. This way, it becomes very clear how cost of goods behaves depending on the different growth scenarios and the potential technology to use.

Taking this one step further: using the same approach, a calculation can be made by plotting the cost per batch vs the number of batches. In this graph you can see all of the options in scope within the graph and clearly see the pay-off at the intersections.

 

References:

https://www.fda.gov
https://www.researchgate.net
http://www.celltherapies.com.au

 

 

 
 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Webinar

Pharmacovigilance and Risk Management in Innovative Therapies: A Challenge in Drug Safety

Explore pharmacovigilance in cell, CAR T, and RNA therapies. Join our webinar to tackle tomorrow’s drug safety and risk management challenges.
preview_image
Webinar

Extractables & Leachables in Pharma: Navigating Evolving Regulations and Toxicological Challenges

This webinar aims to provide a comprehensive overview of Extractables and Leachables (E&L) in pharmaceutical products, highlighting regulatory complexities, toxicological challenges, and practical approaches to study design and risk assessment across the product lifecycle.
preview_image
Whitepaper

A Complete Guide to Computer System Validation

This guide aims to bring context and define the necessary and appropriate strategies for the validation of computerized systems. Download now.
preview_image
Whitepaper

Digital Health - Exploring the landscape and future opportunities

This whitepaper informs you about digital health, key technology pillars, and new opportunities to anticipate future trends in your healthcare sector.
preview_image
Case study

A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader​

QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.
preview_image
Whitepaper

ICH Stability Studies on Pharmaceuticals

This whitepaper discusses the importance of different methods for testing the stability of pharmaceutical products, stability study guidelines, and other aspects related to the stability of pharmaceutical products.
preview_image
Whitepaper

EU GMP: How to import your products into the EU?

Are you a medicinal product manufacturer looking to import your products into the EU in line with the latest EU-GMP import regulations? Download our guide.
preview_image
Case study

Scalable MSAT validation support for seamless compliance & efficiency

Discover how QbD Group helped a global pharmaceutical company address fluctuating validation demands across multiple teams.
preview_image
Case study

Restoring manufacturing timelines through expert deviation management

Discover how QbD Group helped a leading biotechnology company overcome a backlog of deviations, restoring timely batch release through expert QA support.
preview_image
Case study

Guiding a global biotech company through ATMP facility qualification

Discover how QbD Group supported a global biotech company in commissioning and qualifying two ATMP therapy production sites, ensuring compliance and efficiency.
preview_image
Whitepaper

How to keep computerized systems in the operational phase

Ensure compliance and efficiency with best practices for maintaining computerized systems in the operational phase. Download our expert whitepaper now!
preview_image
Whitepaper

Regulatory Affairs for Pharma and Biotech

In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
preview_image
Webinar

Drug-Device Combination Products and Article 117

Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
preview_image
Webinar

Unlocking Strategic Value in Drug Safety for Life Sciences Organizations

Explore how drug safety teams can transform into proactive benefit drivers with the right tools & resources in this webinar on demand.
preview_image
Whitepaper

GAMP 5 Software Validation Approach for GMP, GCP and GLP regulations

Learn how to comply with GMP, GCP, and GLP regulations using the GAMP 5 Software Validation Approach. Download the whitepaper for more insights.
preview_image
Webinar

How to manage mandatory communication of Toxicological Risks?

Learn how to effectively manage toxicological risks in the pharmaceutical industry by addressing, reporting, and mitigating potential harm.
preview_image
Webinar

Setting up ATMP Quality Management Systems: Strategies for Compliance and Success

Discover strategies for establishing a compliant and successful ATMP Quality Management System. Watch our webinar on demand.
preview_image
Webinar

The Basic Concepts of the QbD Methodology

Learn the basics of QbD methodology with industry experts in this on-demand webinar.
preview_image
Webinar

ATMP Supply Chain: Navigating the Challenges and Exploring the Vein-to-Vein Strategy

Explore the transformative ATMP journey and vein-to-vein strategy in our webinar. Learn how to navigate challenges and unlock the full potential of ATMPs.
preview_image
Whitepaper

Achieving laboratory compliance

This whitepaper explores the multifaceted aspects of laboratory compliance, including data integrity, quality control measures, and regulatory adherence.
preview_image
Whitepaper

Annual Product Quality Review in Pharma

Want to learn more about the importance, benefits, and key challenges related to the Annual Product Quality Review in Pharma? Then read on quickly!
preview_image
Whitepaper

New GMP Facility Qualification: set-up, process and best practices

This whitepaper delves into the challenges of establishing a new GMP facility, focusing on potential pitfalls and best practices. Download now.
preview_image
Whitepaper

The One-Vigilance strategic roadmap to corporate excellence

This whitepaper introduces the concept of One Vigilance within the context of the current drug safety landscape. Download now.
preview_image
Case study

Guiding KU Leuven's glioblastoma research to the clinic with precision business planning

Helping KU Leuven advance glioblastoma research to the clinic with strategic business planning, funding support, and a roadmap for clinical impact.
preview_image
Whitepaper

21 CFR Part 11 compliance checklist

Want to assess whether a computer system generates electronic records and uses electronic signatures, and whether the system complies with Part 11 of 21 CFR? Download this free checklist.
preview_image
Whitepaper

Ensuring compliance and quality in Pharmacovigilance

The whitepaper emphasizes the importance of a robust pharmacovigilance QMS and a well-maintained Pharmacovigilance System Master File (PSMF). Download now.
preview_image
Webinar

Second edition of GAMP 5: A Risk-Based Approach to compliant GxP Computerized Systems

This webinar on demand will tell you more about the second edition of GAMP 5.
preview_image
Whitepaper

Organic and mutagenic impurities in pharma

Ensure pharmaceutical quality and safety by controlling organic and mutagenic impurities. Download this whitepaper to learn more.
preview_image
Whitepaper

The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization

Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.
preview_image
Whitepaper

GAMP categories for computerized systems: what are they and what are they for?

In this whitepaper, you will learn what GAMP is, what GAMP categories are for, and where to start if you are facing computerized systems validation.
preview_image
Whitepaper

Analytical Method Validation

In this whitepaper, we will give an overview of the criteria to consider when validating your analytical method.
preview_image
Whitepaper

EUDRALEX Volume 4 Annex 11 Compliance Checklist

Assess your computer system's compliance with EudraLex Volume 4 Annex 11 guidelines using our checklist. Download now for GMP assurance.
preview_image
Whitepaper

From V-model to Agile: how to embrace automation as part of the computerized system validation approach

This white paper explores why IT is shifting to agile, focuses on the prevalent Scrum methodology, and concludes with guidance on adapting system validation processes.
preview_image
Whitepaper

Innovations in ATMP: state of the industry in 2024

This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.
preview_image
Case study

Optimizing pharmacovigilance for a biotechnology leader

Discover how QbD Group improved pharmacovigilance for a global leader in biotechnology, ensuring regulatory compliance and patient safety.
preview_image
Case study

Ensuring timely launch: QbD Group's role in establishing a hemophilia drug production line

QbD Group has facilitated the launch of a new drug production line for treating hemophilia, overseeing the qualification of over 100 pieces of small-scale supporting equipment.
preview_image
Case study

Ensuring pharmaceutical production quality: cleaning validation for government agency

Discover how QbD Group helped a client tackle dual validation challenges for their production lines, ensuring GMP compliance and AEMPS approval.
preview_image
Case study

Revolutionizing pharmacovigilance: a success story of strategic partnership and seamless integration

Discover how QbD Group's expert support enhanced a pharmaceutical company's pharmacovigilance, leading to a favorable inspection outcome by the local Regulatory Authority (AEMPS).
preview_image
Case study

Patient Support Program (PSP)

Learn about our patient support program (PSP) and how it helps manage customer support for a PV Spanish client. Resolve quality issues and ensure stability with QbD Pharma.